NCT00821418已完成不适用
Assessment of the Safety and the Effect on Patients With COPD of Treatment With PulseHaler™ - a Novel Device for Pulsating Positive Expiratory Pressure Ventilation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Pulmonary function tests
研究概览
简要总结
The purpose of the study is to assess the safety and the effect of treatment by PulseHaler™ on patients with COPD, as measured by the change from baseline in full pulmonary functions, oxygen saturation, exercise tolerance and health related quality of life; and to assess the ease of use of PulseHaler™ by the patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of COPD
- •Diagnosis established for at least 1 year;
- •Post-bronchodilator FEV1/FVC < 0.7
- •Post bronchodilator FEV1 <70% predicted
- •Age: 40 years or older
- •Smoking cigarettes, at least 10PY
- •Patient signed the informed consent form
排除标准
- •Bullous Emphysema (ruled out by recent CT)
- •Hospitalization due to exacerbation of COPD within the last 3 months
- •Upper respiratory infection and/or exacerbation of COPD in the last 4 weeks
- •Systemic steroid treatment in the last 4 weeks
- •Women at the age of fertility, who are pregnant, or plan pregnancy, or do not use contraceptive.
- •Severe cardiac disease, e.g., CHF grade 3 or higher
- •Acute MI within last 3 months
- •CABG within last 3 months
- •Other severe systemic disease
结局指标
主要结局
Pulmonary function tests
时间窗: Within 2 hours from first treatment, and after 2 weeks of treatment
Six minute walk test
时间窗: Within 2 hours from first treatment, and after 2 weeks of treatment
Health related quality of life
时间窗: Within 2 hours from first treatment, and after 2 weeks of treatment
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pulsenmore ES Device, Efficacy and Safety AssessmentPerinatal CareNCT05329077PulseNmore188
招募中
不适用
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung CancerNSCLCNCT05987345Energenx Medical LTD.10
撤回
不适用
Exploratory Safety and Effectiveness Evaluation of Pulsed Field Ablation (PFA) by Balloon Catheter With TRUPULSE Generator for Treatment of Paroxysmal Atrial Fibrillation (PAF)Atrial FibrillationNCT06495216Biosense Webster, Inc.30
已完成
不适用
Safety and Effectiveness of an Auricular SprayExcessive Ear WaxNCT06085443YSLab99
已完成
不适用
3-Dimensional Mapping System: The PULSTAR StudyParoxysmal Atrial FibrillationNCT05618340Shanghai Shangyang Medical Technology Co., Ltd.149